搜索此博客

2017年4月24日星期一

CAS NO.:1197-64-5

1197-64-5 ,2-Chloro-6-methyl benzaldehyde, world sole supplier in this chemical.

Each batch could be more than 50kg.

HPLC, 98%+, NMR, MS as attachment.

CAS NO.:1197-64-5
Product Name:2-Chloro-6-methyl benzaldehyde
Synonyms:2-Chloro-6-methyl benzaldehyde
EINECS:
Molecular Formula:
Molecular Weight:

EOS Med ChemMedchem is Big
執大象,天下往,往而無害,安平泰
網址www.eosmedchem.com 
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian

Name: BEC HCl, attachment is NMR, we have 50g in stock.

Name: BEC HCl, attachment is NMR, we have 50g in stock.



Description: BEC, also known as S-(2-boronoethyl)-L-cysteine, is an a slow-binding and competitive Arginase II inhibitor with Ki of 0.31 μM (ph 7.5). BEC significantly enhances NO-dependent relaxation of human penile corpus canvernosum smooth muscle in vitro at concentrations between 0.1-1.0 mM. S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum.
Name: BEC HCl 
CAS#: 222638-67-7 (HCl). 
Chemical Formula: C5H13BClNO4S 
Exact Mass: 
Molecular Weight: 229.482 
Elemental Analysis: C, 26.17; H, 5.71; B, 4.71; Cl, 15.45; N, 6.10; O, 27.89; S, 13.97

Related CAS #: 222638-67-7 (HCl)   63107-40-4 (free base)
Synonym: BEC HCl; S-(2-boronoethyl)-L-cysteine.
IUPAC/Chemical Name: S-(2-boronoethyl)-L-cysteine hydrochloride
InChi Key: GHPYJLCQYMAXGG-WCCKRBBISA-N
InChi Code: InChI=1S/C5H12BNO4S.ClH/c7-4(5(8)9)3-12-2-1-6(10)11;/h4,10-11H,1-3,7H2,(H,8,9);1H/t4-;/m0./s1
SMILES Code: N[C@@H](CSCCB(O)O)C(O)=O.[H]Cl

REFERENCES


1: Kim NN, Cox JD, Baggio RF, Emig FA, Mistry SK, Harper SL, Speicher DW, Morris SM Jr, Ash DE, Traish A, Christianson DW. Probing erectile function: S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum. Biochemistry. 2001 Mar 6;40(9):2678-88. PubMed PMID: 11258879.
2: Kim SH, Langford ML, Boucher JL, Testerman TL, McGee DJ. Helicobacter pylori arginase mutant colonizes arginase II knockout mice. World J Gastroenterol. 2011 Jul 28;17(28):3300-9. doi: 10.3748/wjg.v17.i28.3300. PubMed PMID: 21876618; PubMed Central PMCID: PMC3160534.
3: Martens CR, Kuczmarski JM, Lennon-Edwards S, Edwards DG. Impaired L-arginine uptake but not arginase contributes to endothelial dysfunction in rats with chronic kidney disease. J Cardiovasc Pharmacol. 2014 Jan;63(1):40-8. doi: 10.1097/FJC.0000000000000022. PubMed PMID: 24084210.
4: You H, Gao T, Cooper TK, Morris SM Jr, Awad AS. Arginase inhibition: a new treatment for preventing progression of established diabetic nephropathy. Am J Physiol Renal Physiol. 2015 Sep 1;309(5):F447-55. doi: 10.1152/ajprenal.00137.2015. PubMed PMID: 26041444; PubMed Central PMCID: PMC4556892.
5: You H, Gao T, Cooper TK, Morris SM Jr, Awad AS. Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism. Kidney Int. 2013 Dec;84(6):1189-97. doi: 10.1038/ki.2013.215. PubMed PMID: 23760286; PubMed Central PMCID: PMC3783645.
6: Pudlo M, Demougeot C, Girard-Thernier C. Arginase Inhibitors: A Rational Approach Over One Century. Med Res Rev. 2016 Nov 15. doi: 10.1002/med.21419. [Epub ahead of print] Review. PubMed PMID: 27862081.
7: Bordage S, Pham TN, Zedet A, Gugglielmetti AS, Nappey M, Demougeot C, Girard-Thernier C. Investigation of Mammal Arginase Inhibitory Properties of Natural Ubiquitous Polyphenols by Using an Optimized Colorimetric Microplate Assay. Planta Med. 2016 Oct 24. [Epub ahead of print] PubMed PMID: 27776374.
8: Chu Y, XiangLi X, Niu H, Wang H, Jia P, Gong W, Wu D, Qin W, Xing C. Arginase inhibitor attenuates pulmonary artery hypertension induced by hypoxia. Mol Cell Biochem. 2016 Jan;412(1-2):91-9. doi: 10.1007/s11010-015-2611-z. PubMed PMID: 26608181.
9: Ohnaka M, Okuda-Ashitaka E, Kaneko S, Ando A, Maeda M, Furuta K, Suzuki M, Takahashi K, Ito S. Induction of arginase II mRNA by nitric oxide using an in vitro model of gyrate atrophy of choroid and retina. Invest Ophthalmol Vis Sci. 2011 Mar 18;52(3):1493-500. doi: 10.1167/iovs.10-5516. PubMed PMID: 20811048.
10: McLarren KW, Cole AE, Weisser SB, Voglmaier NS, Conlin VS, Jacobson K, Popescu O, Boucher JL, Sly LM. SHIP-deficient mice develop spontaneous intestinal inflammation and arginase-dependent fibrosis. Am J Pathol. 2011 Jul;179(1):180-8. doi: 10.1016/j.ajpath.2011.03.018. PubMed PMID: 21640975; PubMed Central PMCID: PMC3123870.
11: Ckless K, Lampert A, Reiss J, Kasahara D, Poynter ME, Irvin CG, Lundblad LK, Norton R, van der Vliet A, Janssen-Heininger YM. Inhibition of arginase activity enhances inflammation in mice with allergic airway disease, in association with increases in protein S-nitrosylation and tyrosine nitration. J Immunol. 2008 Sep 15;181(6):4255-64. PubMed PMID: 18768883; PubMed Central PMCID: PMC2892856.
12: Zhang J, Zhang X, Wu C, Lu D, Guo G, Mao X, Zhang Y, Wang DC, Li D, Zou Q. Expression, purification and characterization of arginase from Helicobacter pylori in its apo form. PLoS One. 2011;6(10):e26205. doi: 10.1371/journal.pone.0026205. PubMed PMID: 22028830; PubMed Central PMCID: PMC3197605.
13: Khan M, Steppan J, Schuleri KH, Ryoo S, Tuday E, Bugaj L, Santhanam L, Berkowitz T, Nyhan D, Shoukas AA, Berkowitz DE. Upregulation of arginase-II contributes to decreased age-related myocardial contractile reserve. Eur J Appl Physiol. 2012 Aug;112(8):2933-41. doi: 10.1007/s00421-011-2257-9. Erratum in: Eur J Appl Physiol. 2012 Dec;112(12):4189. Schuleri, Karl [corrected to Schuleri, Karl H]. PubMed PMID: 22160208.
14: Lewis ND, Asim M, Barry DP, Singh K, de Sablet T, Boucher JL, Gobert AP, Chaturvedi R, Wilson KT. Arginase II restricts host defense to Helicobacter pylori by attenuating inducible nitric oxide synthase translation in macrophages. J Immunol. 2010 Mar 1;184(5):2572-82. doi: 10.4049/jimmunol.0902436. PubMed PMID: 20097867; PubMed Central PMCID: PMC2841360.
15: Prieto CP, Krause BJ, Quezada C, San Martin R, Sobrevia L, Casanello P. Hypoxia-reduced nitric oxide synthase activity is partially explained by higher arginase-2 activity and cellular redistribution in human umbilical vein endothelium. Placenta. 2011 Dec;32(12):932-40. doi: 10.1016/j.placenta.2011.09.003. PubMed PMID: 21962305.
16: Chen B, Calvert AE, Cui H, Nelin LD. Hypoxia promotes human pulmonary artery smooth muscle cell proliferation through induction of arginase. Am J Physiol Lung Cell Mol Physiol. 2009 Dec;297(6):L1151-9. doi: 10.1152/ajplung.00183.2009. PubMed PMID: 19801451.
17: Steppan J, Nyhan D, Berkowitz DE. Development of novel arginase inhibitors for therapy of endothelial dysfunction. Front Immunol. 2013 Sep 17;4:278. doi: 10.3389/fimmu.2013.00278. Review. PubMed PMID: 24062745; PubMed Central PMCID: PMC3774993.
18: Zharikov S, Krotova K, Hu H, Baylis C, Johnson RJ, Block ER, Patel J. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol. 2008 Nov;295(5):C1183-90. doi: 10.1152/ajpcell.00075.2008. PubMed PMID: 18784379; PubMed Central PMCID: PMC2584985.
19: Peyton KJ, Ensenat D, Azam MA, Keswani AN, Kannan S, Liu XM, Wang H, Tulis DA, Durante W. Arginase promotes neointima formation in rat injured carotid arteries. Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):488-94. doi: 10.1161/ATVBAHA.108.183392. PubMed PMID: 19164802; PubMed Central PMCID: PMC2662760.
20: Ming XF, Rajapakse AG, Carvas JM, Ruffieux J, Yang Z. Inhibition of S6K1 accounts partially for the anti-inflammatory effects of the arginase inhibitor L-norvaline. BMC Cardiovasc Disord. 2009 Mar 13;9:12. doi: 10.1186/1471-2261-9-12. PubMed PMID: 19284655; PubMed Central PMCID: PMC2664787.

2017年4月17日星期一

PF-06650833,CAS#1817626-54-2

PF-06650833,CAS#1817626-54-2, unti Apr, we have 5g in stock.

Assay more than 98%.

HPLC, NMR, MS is ok.

Price is :



EOS Med ChemMedchem is Big
執大象,天下往,往而無害,安平泰
網址www.eosmedchem.com 
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian

PF-06650833,CAS#1817626-54-21G, USD 2980/G,IN STOCK
PF-06650833,CAS#1817626-54-22G, USD 2920/G,IN STOCK
PF-06650833,CAS#1817626-54-23G, USD 2850/G,IN STOCK
PF-06650833,CAS#1817626-54-25G, USD 2750/G,2 MONTH
PF-06650833,CAS#1817626-54-210G, USD 2450/G,2 MONTH

Rucaparib Intermediate: 1082040-43-4

Rucaparib Intermediate: 1082040-43-4, until 2017.4, we finished more than 100kg production.

About 80kg from GMP plant, approved Site Audit.

Assay more than 99%. HPLC, NMR, COA, MSDS, welcome to my email.

Attaching HPLC.


2017年4月14日星期五

Obeticholic Acid 36 Impurity

Obeticholic Acid 36 Impurity, EOS Med Chem build Obeticholic Acid in 2015, until now, we are one fo TOP supplier.

EOS Med ChemMedchem is Big
執大象,天下往,往而無害,安平泰
網址www.eosmedchem.com 
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian

Obeticholic Acid
化学结构
分子量/化学名
价格


API
C26H44O4 MW:420.63
6α-乙基-3α7α-二羟基-5β-胆烷-24-

Obeticholic Acid Impuirty1
C24H36O4

MW:388.26

3,7-二酮-5β-胆烷-24-

Obeticholic Acid Impuirty2
C48H74O7
MW:763.10
3α-(3α-羟基-7--5β-胆烷-24-酰基氧基) -7--5β-胆烷-24-

Obeticholic Acid Impuirty3
C24H38O4
MW:390.56

Obeticholic Acid Impuirty4
C26H44O5
MW: 436.62
3α,6α,7α-三羟基-5β-胆烷-24-酸乙酯

Obeticholic Acid Impuirty5
C26H40O4
MW:416.59
3,7-二酮-5β-胆烷-24-酸乙酯

Obeticholic Acid Impuirty6
C28H44O5
MW:460.65


Obeticholic Acid Impuirty7
C50H78O7
MW:791.15


Obeticholic Acid Impuirty8
C28H46O5
MW:462.66


Obeticholic Acid Impuirty9
C28H42O4MW:442.63
6-亚乙基-3,7-二酮-5β-胆烷-24-酸乙酯

Obeticholic Acid Impuirty10
C28H46O5MW:462.66
3α-(甲氧基甲基氧基)-7--5β-胆烷-24-酸乙酯

Obeticholic Acid Impuirty11
C26H42O4MW:418.61

6α-乙基-3α-羟基-7--5β-胆烷-24-

Obeticholic Acid Impuirty12
C28H46O5MW:462.66
6β-乙基-3α-(甲氧基甲基氧基)-7--5β-胆烷-24-

Obeticholic Acid Impuirty13
C26H42O5 MW:434.61
3α-(甲氧基甲基氧基)-7--5β-胆烷-24-

Obeticholic Acid Impuirty14
C28H44O5 MW:460.32


Obeticholic Acid Impuirty15
C30H50O6 MW:506.71


Obeticholic Acid Impuirty16
C30H48O6 MW:504.70


Obeticholic Acid Impuirty17
C24H40O4 MW::392.57

7α-羟基-5β-胆甾烷-24-

Obeticholic Acid Impuirty18
C24H40O5 MW:408.57

7α-三羟基-5β-胆甾烷-24-

Obeticholic Acid Impuirty19
C48H78O7 MW:767.13
3α-7α-二羟基-5β-胆烷-24-酰基氧基)-7α-羟基-5β-胆烷

Obeticholic Acid Impuirty20
C24H40O4 MW:392.57


Obeticholic Acid Impuirty21
C24H40O5 MW:408.57


Obeticholic Acid Impuirty22
C24H40O3 MW:376.57


Obeticholic Acid Impuirty23
C24H40O4 MW:392.57


Obeticholic Acid Impuirty24
C24H40O5 MW:408.57


Obeticholic Acid Impuirty25
C25H42O4 MW:406.60


Obeticholic Acid Impuirty26
C24H40O4 MW:392.57

7α-二羟基-5β-胆烷-24-

Obeticholic Acid Impuirty27
C26H42O4 MW:418.61

6-亚乙基-3α7α-二羟基-5β-胆烷-24-

Obeticholic Acid Impuirty28
C26H42O4 MW:418.61

6α-乙基-3α羟基-7 –-5β-胆烷-24-

Obeticholic Acid Impuirty29
C26H44O4 MW:420.63

6β-乙基-3α7α-二羟基-5β-胆烷-24-

Obeticholic Acid Impuirty30
C26H44O4
MW:420.63

6α-乙基-3α7β-二羟基-5β-胆烷-24-

Obeticholic Acid Impuirty31
C26H44O4 MW:420.63

6β-乙基-3α7β-二羟基-5β-胆烷-24-

Obeticholic Acid Impuirty32
C52H86O7
MW:823.24

3α-(3α7α-二羟基-6α-乙基-5β-胆烷-24-酰基氧基) -6α-乙基-7α-羟基-5β-胆烷-24-

Obeticholic Acid Impuirty33
C27H46O4
MW:434.65


Obeticholic Acid Impuirty34
C28H48O4
MW:448.68


Obeticholic Acid Impuirty35
C26H46O3
MW:406.64


Obeticholic Acid Impuirty36
C26H40O4
MW:416.59